Detalhe da pesquisa
1.
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell
; 185(3): 563-575.e11, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120664
2.
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.
Nat Immunol
; 23(8): 1183-1192, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902637
3.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
N Engl J Med
; 388(19): 1767-1778, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163623
4.
Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
Cancer
; 130(5): 692-701, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864521
5.
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Lancet
; 401(10379): 821-832, 2023 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774933
6.
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
Oncologist
; 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38280218
7.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
8.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
J Natl Compr Canc Netw
; 22(1): 4-16, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394781
9.
Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
Cancer
; 129(24): 3952-3961, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37715631
10.
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy.
Future Oncol
; 19(2): 113-121, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36752726
11.
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(2): 292-303, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35032437
12.
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(7): 888-898, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35688173
13.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383908
14.
Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges.
N Engl J Med
; 390(15): 1432-1433, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38631007
15.
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1103-1115, 2019 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30779531
16.
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(1): 71-90, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34991070
17.
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Acta Oncol
; 61(1): 52-57, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34736367
18.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lancet Oncol
; 22(7): 946-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143969
19.
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.
Cancer
; 127(21): 3946-3956, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34286865
20.
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
Br J Cancer
; 124(1): 237-246, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024271